


## PHARMACEUTICAL 2018

## Aimmune Therapeutics Inc. Rank 227 of 349





## PHARMACEUTICAL 2018

## Aimmune Therapeutics Inc. Rank 227 of 349

The relative strengths and weaknesses of Aimmune Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aimmune Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 210% points. The greatest weakness of Aimmune Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 181% points.

The company's Economic Capital Ratio, given in the ranking table, is -286%, being 8.6% points below the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	189,111
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	26,599
Liabilities, Non-Current	2,530
Other Assets	618
Other Compr. Net Income	-81
Other Expenses	56
Other Liabilities	0
Other Net Income	2,005
Property and Equipment	17,205
Research and Development	89,325
Revenues	0
Selling, General and Administrative Expense	43,949

Output Variable	Value in 1000 USD
Assets	206,934
Liabilities	29,129
Expenses	133,330
Stockholders Equity	177,805
Net Income	-131,325
Comprehensive Net Income	-131,366
Economic Capital Ratio	-286%